Millipore Sigma Vibrant Logo

171260 AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem

View Products on Sigmaaldrich.com
171260
가격 및 재고 조회

개요

Replacement Information

주요 사양표

CAS #Empirical Formula
866405-64-3C₂₄H₂₅N₅O

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
171260-10MGCN
재고 정보 검색...
현재 재고 없음
현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      Plastic ampoule 10 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      가격 문의
      171260-1MGCN
      재고 정보 검색...
      현재 재고 없음
현재 재고 없음
      예상 출고 가능일 
      단종품
      제한된 수량 가능
      재고여부 확인
        Remaining: will advise
          Remaining: will advise
          추천사항
          고객 서비스로 문의
          Contact Customer Service

          Plastic ampoule 1 mg
          가격 검색...
          가격을 검색할 수 없습니다
          Minimum Quantity needs to be mulitiple of
          Maximum Quantity is
          가격 문의 추가 정보
          ()이 할인됨
           
          가격 문의
          171260-5MGCN
          재고 정보 검색...
          현재 재고 없음
현재 재고 없음
          예상 출고 가능일 
          단종품
          제한된 수량 가능
          재고여부 확인
            Remaining: will advise
              Remaining: will advise
              추천사항
              고객 서비스로 문의
              Contact Customer Service

              Plastic ampoule 5 mg
              가격 검색...
              가격을 검색할 수 없습니다
              Minimum Quantity needs to be mulitiple of
              Maximum Quantity is
              가격 문의 추가 정보
              ()이 할인됨
               
              가격 문의
              Description
              OverviewA cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo. Also available as a 10 mM solution in DMSO (Cat. No. 171261).
              Catalogue Number171260
              Brand Family Calbiochem®
              Synonyms6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
              References
              ReferencesHao, J., et al. 2010. ACS Chem.Biol. 5, 245.
              Yu, P.B., et al. 2008. Nat. Chem. Biol 4, 33.
              Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
              Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
              Inoki, K., et al. 2003. Cell 115, 577.
              Fryer, L.G., 2002. FEBS Lett. 531, 189.
              Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.
              Product Information
              CAS number866405-64-3
              ATP CompetitiveY
              FormLight yellow solid
              Hill FormulaC₂₄H₂₅N₅O
              Chemical formulaC₂₄H₂₅N₅O
              ReversibleY
              Structure formula ImageStructure formula Image
              Quality LevelMQ100
              Applications
              Biological Information
              Primary TargetAMPK
              Primary Target IC<sub>50</sub>25.1, 148, and 234.6 nM, against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity, respectively
              Primary Target K<sub>i</sub>EC100 = 2.5 µM against BMP pathway-dependent dorsoventral development; EC50 = 5 µM against VEGF signaling-dependent intersomitic vessel formation in zebrafish embryo in vivo
              Purity≥95% by HPLC
              Physicochemical Information
              Cell permeableY
              Dimensions
              Materials Information
              Toxicological Information
              Safety Information according to GHS
              Safety Information
              Product Usage Statements
              Storage and Shipping Information
              Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
              Toxicity Standard Handling
              Storage +2°C to +8°C
              Protect from Light Protect from light
              Do not freeze Ok to freeze
              Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
              Packaging Information
              Packaged under inert gas Packaged under inert gas
              Transport Information
              Supplemental Information
              Specifications
              Global Trade Item Number
              카탈로그 번호 GTIN
              171260-10MGCN 04055977207156
              171260-1MGCN 04055977207149
              171260-5MGCN 04055977207163

              Documentation

              AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem MSDS

              타이틀

              물질안전보건자료(MSDS) 

              AMPK Inhibitor, Compound C - CAS 866405-64-3 - Calbiochem Certificates of Analysis

              TitleLot Number
              171260

              References

              참고문헌 보기
              Hao, J., et al. 2010. ACS Chem.Biol. 5, 245.
              Yu, P.B., et al. 2008. Nat. Chem. Biol 4, 33.
              Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
              Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
              Inoki, K., et al. 2003. Cell 115, 577.
              Fryer, L.G., 2002. FEBS Lett. 531, 189.
              Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.
              Data Sheet

              Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

              Revision22-March-2012 JSW
              Synonyms6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine, Dorsomorphin, AMPK Inhibitor I, BMP Inhibitor I
              DescriptionA cell-permeable pyrrazolopyrimidine compound that inhibits against KDR/VEGFR2, ALK2/BMPR-I, AMPK kinase activity (IC50 = 25.1, 148, and 234.6 nM, respectively), while exhibiting much reduced or little effect toward ALK5/TGFβR-I, ZAPK, Syk, PKCθ, PKA, or JAK3. Shown to block both BMP pathway-dependent dorsoventral development (EC100 = 2.5 µM) and VEGF signaling-dependent intersomitic vessel formation (EC50 = 5 µM) in zebrafish embryo in vivo. Commonly used in combination with AMPK activators AICAR (Cat. No. 123040) and/or Metformin (Cat. No. 317240) for studying AMPK-dependent cellular events in vitro and physiological responses in animals in vivo. Also available as a 10 mM solution in DMSO (Cat. No. 171261).
              FormLight yellow solid
              Intert gas (Yes/No) Packaged under inert gas
              CAS number866405-64-3
              Chemical formulaC₂₄H₂₅N₅O
              Structure formulaStructure formula
              Purity≥95% by HPLC
              SolubilityDMSO (4 mg/ml), 2% HCl (10 mg/ml), 2% Acetic Acid (10 mg/ml), or Methanol (3 mg/ml)
              Storage Protect from light
              +2°C to +8°C
              Do Not Freeze Ok to freeze
              Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
              Toxicity Standard Handling
              ReferencesHao, J., et al. 2010. ACS Chem.Biol. 5, 245.
              Yu, P.B., et al. 2008. Nat. Chem. Biol 4, 33.
              Kim, E.K., et al. 2004. J. Biol. Chem. 279, 19970.
              Lee, M., et al. 2003. J. Biol. Chem. 278, 39653.
              Inoki, K., et al. 2003. Cell 115, 577.
              Fryer, L.G., 2002. FEBS Lett. 531, 189.
              Zhou, G., et al. 2001. J. Clin. Invest. 108, 1167.